AFH Holding & Advisory

AFH Holding & Advisory LLC is a boutique investment banking firm that offers financial advisory services. The firm focuses on alternative public offerings marketing strategy planning capital structuring and mergers and acquisitions advisory. Its clientele include Carlisi Natural Gas Inc. Fossil Energy Group LLC Kaikai Technology Co. Ltd. and Yi Xin Copper Co. Ltd. AFH Holding & Advisory LLC is based in Beverly Hills California with an additional office in Pudong China.
Amir Heshmatpour
Founder & Managing Director 

Aisling Capital

Aisling Capital is a private equity group based in New York with over $1.6 billion in assets under management. Aisling is currently looking for new firms for potential investments for the firm?s third fund. The firm looks to make investments in companies seeking to raise a total round of $2-5 million. The firm looks to invest in companies globally with a focus on companies located in the United States.
Dennis Purcell
Founder and Senior Advisor 

Apple Tree Partners United States

Apple Tree Partners is a private equity fund that was established in 1999 and based in New York, NY, with satellite offices in Princeton, NJ, Cambridge, MA and Brussels, Belgium. The firm controls up to $1.75 billion in assets under management and makes equity investments ranging from $100,000 for academic spinouts to $150 million dollar in later stage deals. The firm seeks to make investments around the globe with a focus on creating and building companies located within the US and Europe.

Year Founded
1999
Investor Type
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Sam Hall
Principal 
Aaron Kantoff
Vice President 

Arcus Ventures United States

Arcus Ventures was founded in 2007 and is based in New York City. Arcus Ventures is currently investing from its second fund, which had a first close of $36m in 2014 and is targeting a raise of $100m. The firm typically invests $2-5 million. Arcus invests primarily in the USA but is also open to considering opportunities in Canada.

Myoung-Ok Kwon
Venture Partner 

ATEM Capital

ATEM Capital manages evergreen Life Sciences investment fund - Health Square Fund (HSF). HSF acts as a consolidator of capital flows from the Emerging Markets and invests into the biotech innovation hubs of the US/Western Europe. HSF's international team combines big-picture business perspective with decades of investment scientific legal portfolio risk management and operational experience. The fund is audited by a Big-4 firm. Our Advisory Board comprises high-caliber entrepreneurs VC veterans and seasoned Wall Street professionals.
Alexey Afanasiev
Executive Partner 
Anton Gopka
CEO General Partner 
Elena Ikhsanova
COO General Partner 

Baxter Ventures

Baxter Ventures is the strategic venture arm of Baxter International Inc. that was formed in 2011 and is based in Deerfield, Illinois. The firm is currently making equity investments out of a $200 Million fund with allocations generally falling in the $3-$5 million range. The firm is looking in invest in companies who have previously or are currently in the process of securing investment from other institutional investors. The firm is willing to look globally for investment opportunities and plans to make approximately 2 new investments over the next 6-9 months.

Priyanka Rohatgi
Director 

BSI Capital Group

BSI Capital is a Single Family Office based in Mexico City Mexico. The firm is looking to make growth stage investments into healthcare companies generally in series C and D rounds or later. Due to the structure of the firm BSI has a highly variable investment size that will depend of the financial needs of the company. The firm is currently looking for new opportunities throughout the United States Mexico and Canada. The firm has no set number of investment in plans to make over the next 6-9 months.
Alejandra Paradones
CEO & Founder 

Correlation Ventures United States

Correlation Ventures is a venture capital firm that founded in 2010 and is based in San Diego, California with an additional office in Palo Alto, California. The firm currently has approximately $165 million in total assets under management. The firm typically makes investments ranging from $0.25 million to $5 million over the life of the company, and the first investment will be not larger than $2.5 million. The firm’s preferred capital structure is convertible preferred equity or convertible loan. Correlation Ventures will consider invest in any industry segment at any stage, but there must be at least one other venture capital firm making their first investment in the company in this round. The firm only invests in US-based companies. 

Correlation is extremely opportunistic when it comes to investments in the life sciences space; with that being said the firm's specified sectors and sub sectors of interest may or may not be an area in which Correlation Ventures is currently looking to allocate capital to. The firm has made a number of investments in companies in the life sciences space, and has mainly invested in companies in the biotech therapeutics and diagnostics space. The firm's current portfolio includes biotech therapeutics and diagnostics firms developing products targeting endocrine, metabolic, and nutritional diseases, musculoskeletal system and connective tissue, neoplasms, cancer, and oncology, genitourinary system, and infectious and parasitic diseases.

Year Founded
2010
Investor Type
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
David Coats
Managing Director 

DavosPharma United States

DavosPharma’s corporate offering covers all the activities required to get a drug from conception to commercialization. DavosPharma has been filling this need since 1972, serving the pharmaceutical and life science market by providing discovery chemistry & biology, pre-clinical development, and all required CMC activities including custom synthesis of organic molecules, custom dosage formulation, and custom manufacturing of cGMP intermediates, APIs, and drug product. 

Gifford Marzoni
Vice-President Global Pharmaceutical Development 
Mike Shore
Director, Global Supply Chain & Technical Operations